Qiagen N.V. Common Shares (QGEN)
Stock · NYSE · Health Care
$46.13as of 10/16/2026
Price chart
Active signals
QGEN Signal Track Record
How signals performed across all stocks →What QGEN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| 200-Day Moving Average TouchActive now | 32 | -0.4% | 47% | October 1, 2026 |
| Volume Spike | 24 | -0.2% | 46% | September 23, 2026 |
| Bollinger Band Breakout | 23 | -1.1% | 43% | August 10, 2026 |
| Bollinger Band Breakdown | 21 | -1.1% | 38% | April 23, 2026 |
| Any 20-session window (baseline) | +0.4% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About QGEN
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary samp…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 5,500
- Website
- www.qiagen.com/
Fundamentals
- 1-day range
- $44.8$46.09
- Market cap
- $8.60B
- P/E (trailing)
- 22.92
- P/E (forward)
- 17.22
- EPS (trailing)
- $1.94
- Dividend yield
- 0.83%
- Beta
- 0.60
- Avg. volume
- 2.75M
- Ex-dividend date
- July 7, 2026
- Dividend pay date
- July 14, 2026
Forecasts
15 analyst ratings
Qiagen N.V. Common Shares Competitors
Chosen by industry and closest market cap.
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
- IBRXImmunityBio Inc. Common Stock$9.18▼ 8.20%Market cap $7.76BP/E —$1.95$12.43
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
| IBRX ImmunityBio Inc. Common Stock | $7.76B | — | $9.18 | ▼ 8.20% | $1.95$12.43 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared PanelYahoo · 10/2/2026
- Biomarkers Market Forecasts Growth from $67.95B (2026) to $112.10B by 2031, Profiling Roche, Abbott, Thermo Fisher & QiagenYahoo · 10/1/2026
- Qiagen (QGEN), What Is Behind The Fresh Attention Now?Yahoo · 9/29/2026
- What Qiagen (QGEN)'s Expanded Sepsis Testing Portfolio Means For ShareholdersYahoo · 9/29/2026
- Magnetic Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and Miltenyi Biotec Battle for LeadershipYahoo · 9/28/2026
- QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection PanelYahoo · 9/28/2026
- FDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance MarkerBenzinga · 9/28/2026
- QIAGEN Launches QIAmini to Automate Small-Batch Sample PreparationYahoo · 9/24/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
QIAGEN FDA Clears New Sepsis Testing Panel
QIAGEN received FDA clearance for a new Gram-negative bacteria detection panel, completing its US QIAstat-Dx bloodstream infection portfolio. This expansion allows the company to cover 33 pathogen targets and 28 resistance markers, strengthening its position in the sepsis testing market. The move aligns with broader industry growth forecasts for biomarkers and positions the company to compete effectively against major diagnostics rivals.
QIAGEN FDA Clears New Sepsis Testing Panel. QIAGEN received FDA clearance for a new Gram-negative bacteria detection panel, completing its US QIAstat-Dx bloodstream infection portfolio. This expansion allows the company to cover 33 pathogen targets and 28 resistance markers, strengthening its position in the sepsis testing market. The move aligns with broader industry growth forecasts for biomarkers and positions the company to compete effectively against major diagnostics rivals.